Hunan Paizhi Biotechnology Co., Ltd. is a scientific and technological innovation enterprise integrating research and development, production and operation of new biological products for animals, and has a wholly-owned subsidiary of Hunan New Generation Animal Vaccine Research Institute Co., Ltd. The company has successfully created a series of biological nanomaterials-virus-like particles (VLPs) with independent intellectual property rights. VLPs have strong immunogenicity, high stability and high biological safety (zero pathogenic risk). Based on Changsha High-tech Industrial Development Zone, Pizhi Biotech will focus on high-end vaccine research and development, production and testing services, and build a domestic and international leading "precision animal vaccine" research and development and production.

Paizhi Biology has international top talents, such as national outstanding youth, experts of Hunan Hundred Talents Program, and a high-end animal vaccine research team with core competitiveness, mainly composed of doctors and masters, and composed of top talents in the industry. The company has established industry-university-research cooperation with more than 10 universities and institutes at home and abroad, including Peking University, Chinese Academy of Sciences, Hunan University and Hunan Agricultural University, to carry out scientific research on the new generation of animal vaccine, actively promote industrialization, improve the research and development system and product pipeline, incubate the new generation of animal vaccine industry cluster, and form a new generation of "precision animal vaccine" technological innovation highland and advanced manufacturing highland.

In recent years, the company has applied for and obtained a number of industrial patents for virus-like particle vaccines, and has made major breakthroughs in the research and development and industrialization of VLPs vaccines for several infectious diseases such as African swine fever, blue-ear disease, swine epidemic diarrhea, circovirus disease, avian influenza, etc., and is leading the industry in the design and R&D innovation of vaccines based on protein 3D structure. At the same time, The company has a complete evaluation system in the detection of various animal diseases and the evaluation of vaccine immune effect, and has fully independent intellectual property rights. It represents the direction of global vaccine research, will lead the upgrade of veterinary vaccines, and help the prevention, control and purification of animal viral diseases in China.